The newspaper Nature published in Juin 2014 an article on phage therapy.
The journal pharmaceutiques published in April 2014 an article about new ways to fight against multidrug-resistant bacteria.
Two new french articles were published in January 2014 on Phage therapy.
A progress meeting of the European Phagoburn project took place on November 26, 2013 at Saint Luc Saint Joseph hospital in Lyon.
Jérôme Gabard: CEO
|Starting at the bench in DuPont de Nemours plant biotechnology research facility (Wilmington, DE, USA) in the late eighties, Jérôme has been since developing professional skills in marketing and business development.
Prior to join Pherecydes Pharma he was Life Sciences Director at The Marketech Group, to develop company sales and to perform strategic and operational market research studies for start up’s or big pharma.
He is experienced in managing private innovative R&D start up’s (Euroclide) and to build value through merger-acquisition (Faust Pharmaceuticals, today Domain Therapeutics).
During his career he has been involved in a variety of R&D industrial projects, related to plant biotechnology, crop protection, food pathogen diagnostics, information management and drug discovery.
Flavie Pouillot: Head of R&D
|Flavie Pouillot is in charge of driving and managing research & development effort at Pherecydes Pharma.
Prior to join the company, Flavie Pouillot lead a research program at the Institut Pasteur in Paris addressing the highly sensitive subject of protection against Yersinia pestis, the agent of plague, one of the major threats associated with bioterrorism.
She used directed mutagenesis to further understand infection pathogenicity mechanisms.
Flavie holds a PhD in microbiology, with expertise in molecular biology, from the Institut Pasteur and University Pierre & Marie-Curie in Paris, France. She signed several publications in peer-reviewed publications from international journals.